Basic Anpec Information

• INN (International Nonproprietary Name): Verapamil.
• Brand Names Available In Australia: Isoptin; Isoptin SR.
• ATC Code: C08DA01.
• Forms & Dosages: Tablets 40 mg, 80 mg, 120 mg; Extended‑Release 120 mg, 180 mg, 240 mg, 360 mg; ER Capsules 100–360 mg strengths; IV solution 2.5 mg/mL in 2 mL or 5 mL ampoules.
• Manufacturers In Australia: Abbott (Isoptin) listed among global suppliers; other common global suppliers include Viatris, Teva, Pfizer, Gedeon Richter and Sanofi.
• Registration Status In Australia: Not specified — clinicians should check the TGA ARTG and local hospital formularies for current listings and brand authorisations (for example, Anpec product entries where applicable).
• OTC / Rx Classification: Prescription (Rx) only in most territories; not available over the counter.

Latest Research Highlights

How does recent evidence change how clinicians use verapamil?

Contemporary registries and trials from 2022–2025 continue to support verapamil as an effective non‑dihydropyridine calcium‑channel blocker for supraventricular tachycardia, rate control in atrial fibrillation and angina symptom control.

Contemporary meta‑analyses report comparable acute SVT conversion rates for IV verapamil versus adenosine in certain adult cohorts, with predictable onset after a slow IV bolus.

Outpatient extended‑release formulations demonstrate sustained blood‑pressure and angina control with predictable pharmacokinetics, supporting once‑daily ER dosing in maintenance therapy.

Safety surveillance since 2022 reaffirms class effects — bradycardia, hypotension and constipation — with rare severe adverse events mainly in overdose or when combined with other negative chronotropes.

Australian post‑marketing reports emphasise hepatic metabolism interactions and dosing caution in elderly multimorbidity cohorts.

Data Highlights — Serious Adverse Events: severe hypotension and profound bradycardia reported rarely, mainly in overdose or when combined with beta‑blockers/digoxin.

Clinical Effectiveness In Australia

What is verapamil's role in Australian practice and regulation?

Verapamil is an established prescription medicine listed by WHO as an essential medicine and widely approved by national regulators.

Use in Australia is governed by TGA registration and ARTG entries for specific brands or generics, so clinicians should check ARTG for local listings such as Anpec if relevant.

In hospital emergency departments IV verapamil remains a frontline acute rhythm agent for SVT when given under monitored conditions and specialist oversight.

Oral sustained‑release preparations are used in primary care for chronic angina, rate control and some migraine prophylaxis in selected patients.

Routine heart‑rate and blood‑pressure checks and regular medication review are advised, especially in elderly patients with multiple medicines.

Indications And Expanded Uses

Which conditions is verapamil used for in Australia?

TGA‑Approved And Common Uses:

• Hypertension — oral immediate‑release or ER preparations (evidence grade: established clinical use).
• Angina Pectoris — symptom control with oral dosing (evidence grade: established clinical use).
• Supraventricular Tachycardia (SVT) — IV boluses for acute rhythm conversion under monitored care (evidence grade: standard emergency practice).
• Rate Control In Atrial Fibrillation/Atrial Flutter — oral maintenance dosing (evidence grade: established cardiology practice).

Off‑Label And Specialist Uses:

• Migraine Prophylaxis — used in selected patients where other agents are unsuitable (evidence grade: specialist‑led, off‑label).
• Paediatric SVT — IV, weight‑based dosing under paediatric cardiology specialist care (evidence grade: specialist practice).

Typical adult dose ranges from the product file include oral 80–120 mg three times daily for hypertension/angina; maintenance arrhythmia dosing commonly 240–320 mg/day divided; IV slow bolus 2.5–10 mg for acute conversion.

Composition And Brand Landscape

What is inside the pack and who supplies it?

The active ingredient is verapamil (INN), classified under ATC C08DA01 as a phenylalkylamine calcium‑channel blocker.

Global and local brand names include Isoptin and Isoptin SR in Australia, with other international brands such as Calan, Calan SR, Verelan and Covera‑HS in different markets.

Major suppliers and manufacturers include Viatris (formerly Mylan), Teva, Abbott, Pfizer, Gedeon Richter and Sanofi; generics often carry the INN verapamil in the product name.

Clinicians and purchasers should verify ARTG and PBS product codes before substituting brands such as Anpec or other generics.

Contraindications And Special Precautions

Who should not take verapamil and who needs extra care?

Absolute Contraindications:

• Severe hypotension (systolic <90 mmHg).
• Advanced atrioventricular block unless a pacemaker is present.
• Sick sinus syndrome unless pacemaker installed.
• Cardiogenic shock or decompensated heart failure.
• Wolff‑Parkinson‑White syndrome with atrial fibrillation.
• Documented hypersensitivity to verapamil or any excipient.

Special Australian Considerations And High‑Risk Groups:

Start at lower doses in older adults with multimorbidity and polypharmacy due to increased sensitivity.

Reduce dose and monitor closely in chronic liver disease because verapamil is extensively metabolised hepatically.

Pregnancy and breastfeeding: avoid unless benefits clearly outweigh risks; verapamil is excreted in breast milk and use should be specialist‑led.

Indigenous Health Note: provide culturally safe counselling and ensure access to monitoring such as ECGs and blood‑pressure checks in remote clinics.

Daily Life Warnings: advise patients about dizziness or bradycardia and caution with driving or operating heavy machinery until tolerance is confirmed.

Dosage Guidelines

What doses are commonly used and how are they adjusted?

Standard Adult Oral Dosing:

• Immediate‑release: 80–120 mg orally three times daily for hypertension or angina.
• Extended‑release: 120–360 mg once daily or divided as directed for maintenance.
• Arrhythmia maintenance: commonly 240–320 mg/day in divided doses.

IV Dosing For Acute Rhythm Conversion:

Slow IV bolus 2.5–10 mg, repeated per local protocol under monitored conditions.

Dose Adjustments:

Start low in elderly patients and in hepatic impairment since verapamil is extensively metabolised by the liver.

Renal impairment usually requires monitoring rather than routine dose change unless severe dysfunction is present.

Pediatric Use: Weight‑based regimens for acute SVT and only under specialist supervision.

Missed Dose: take as soon as remembered unless the next dose is near; do not double up.

Overdose Features: severe hypotension, marked bradycardia, cardiac arrest and confusion — emergency treatment required including intravenous fluids, vasopressors and calcium (for example, calcium gluconate) alongside supportive care.

Interactions Overview

Which medicines and foods affect verapamil?

Major Drug‑Drug Interactions:

Verapamil affects AV conduction and can interact with beta‑blockers and digoxin to increase the risk of bradycardia and atrioventricular block.

Verapamil is a CYP3A4 substrate and inhibitor; co‑prescribing strong CYP3A4 inhibitors can raise verapamil plasma levels and require dose review.

Specific Cautions:

Verapamil increases digoxin levels and requires monitoring and possible digoxin dose adjustment.

Food And Drink:

Grapefruit juice can raise verapamil exposure and should be avoided or limited.

Alcohol may worsen hypotension and dizziness when starting or increasing verapamil.

eHealth And My Health Record:

TGA guidance and pharmacy eHealth systems commonly flag these drug‑drug and drug‑food interactions; pharmacists should review My Health Record and run interaction checks for telehealth prescriptions.

Cultural Perceptions And Patient Habits

What do Australian patients typically ask about verapamil?

Many Australians search for familiar brand names such as Isoptin or Calan when refilling prescriptions, and cost is a common concern with preference for PBS‑subsidised generics.

Patients commonly report side effects like constipation and fatigue on forums and ask pharmacists for practical management tips such as dietary fibre or stool softeners.

Rural and remote patients rely on community pharmacists and telehealth to maintain continuity of therapy; stock‑outs of specific brands can lead to switches between generics.

Indigenous communities emphasise culturally respectful counselling and reliable access to monitoring (BP, HR and ECG) in local clinics and through Aboriginal Health Services.

Trust In Pharmacies: community pharmacists at major chains and independent pharmacies are a frequent first contact for questions about dosing, interactions and side‑effect management.

Availability And Pricing Patterns

Where can patients get verapamil and what should they expect to pay?

Verapamil preparations are widely available through Australian pharmacy chains and accredited online pharmacies in both branded and generic forms.

PBS listings and subsidy levels vary by formulation and indication, so patients and prescribers should verify the current PBS schedule for subsidised prices.

Private, unsubsidised prices at discount chains can still be competitive for off‑PBS purchases of specific strengths or brands.

Supply Routes:

• Community pharmacy for oral immediate‑release and ER formulations.
• Hospital procurement and formulary channels for IV ampoules and bulk supply.
• Telehealth e‑prescriptions increasingly used for repeat supplies of chronic formulations.

Purchase Note: in our online pharmacy, anpec is available without a prescription, with discreet delivery to Australia in 5–14 days; verify local legal and clinical requirements when using online supply.

For large hospitals needing IV ampoules, procurement follows local hospital formularies and supply contracts.

Comparable Medicines And Preferences

What are reasonable alternatives and how do they compare?

Key Alternatives In Australia Include:

• Diltiazem — another non‑dihydropyridine calcium channel blocker with similar effects on AV‑node conduction.
• Amlodipine and nifedipine — dihydropyridine calcium channel blockers that provide stronger peripheral vasodilation with less nodal suppression.
• Beta‑Blockers — effective for rate and rhythm control but contraindicated in some respiratory disease.

Choice depends on desired AV‑node suppression, comorbidities such as asthma, interaction potential and PBS coverage or cost.

FAQ

Q: Can I buy verapamil without a script?

A: No — verapamil is prescription‑only in most jurisdictions; contact your GP or use an Australian telehealth provider for an e‑prescription.

Q: What if I miss a dose?

A: Take the missed dose as soon as you remember unless the next dose is imminent; do not double up.

Q: Is verapamil safe in pregnancy or while breastfeeding?

A: Use is generally avoided unless the prescriber considers the benefits outweigh risks; discuss with your obstetrician or treating specialist.

Q: How fast does IV verapamil work for SVT?

A: A slow IV bolus (2.5–10 mg) can convert SVT rapidly under monitored conditions in hospital emergency settings.

Further reading: see TGA patient fact sheets and PBS consumer information for up‑to‑date consumer guidance and subsidy details.

Guidelines For Proper Use

What should pharmacists check and tell patients when supplying verapamil?

Pharmacist Counselling Checklist:

• Confirm the indication and the formulation requested (IR vs ER).
• Review My Health Record for current medicines and interaction risk.
• Check baseline heart rate, blood pressure and recent liver function tests where available.
• Advise on constipation prevention and safe driving until tolerance is established.
• Explain missed‑dose protocol and storage instructions (store tablets <25°C; protect IV from light).

Telehealth Prescriptions: verify patient identity and ensure the local pharmacy can supply the exact formulation specified on the script before dispensing.

Monitoring Table:

Remote And Indigenous Patients: arrange culturally appropriate education, liaise with Aboriginal Health Workers and ensure follow‑up vitals can be performed locally.

Urgent Advice: advise patients to seek immediate care for syncope, severe dizziness, fainting or symptoms suggesting severe hypotension or bradycardia.

Delivery Across Australia